Grade 3 or higher anorexia ( 13 [ 5 % ] vs three [ 1 % ] ; p = 0019 ) and diarrhoea ( 23 [ 9 % ] vs seven [ 3 % ] ; p = 00040 ) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab .